Robert Copeland

Robert Copeland

Company: Accent Therapeutics

Job title: President, Chief Scientific Officer and Co-Founder


Robert A. Copeland, Ph.D. founded Accent Therapeutics in September, 2017 and serves as its President & Chief Scientific Officer. He is also President of the independent consulting firm Ki Consultant, LLC. He was formerly President of Research and Chief Scientific Officer of Epizyme, Inc. and before that, Vice President of Cancer Biology, Oncology Center of Excellence in Drug Discovery, GlaxoSmithKline. Dr. Copeland received his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology. He has contributed to drug discovery and development efforts leading to 19 investigational new drugs entering human clinical trials. These include the cancer drugs Tazverik (tazemetostat), Tafinlar (dabrafenib) and Mekinist (trametinib) and the antibiotic Altabax (retapamulin). Dr. Copeland has contributed more than 200 publications to the scientific literature (h-index = 67; > 26,000 total citations), holds 14 issued U.S. patents and has authored 5 books in the areas of protein science and enzymology. His most recent book, Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, 2nd Edition (Wiley, Hoboken, NJ), published in March 2013. In 2016 Dr. Copeland was elected a Fellow of the American Association for the Advancement of Science (AAAS). 


Panel: Our Social Media Feeds Are Personalized – Why Isn’t Our Medical Treatment? 1:00 pm

The journey to personalized medicine and the role epigenetics will play  How to design a drug development pipeline for precision medicine  The future of personalised medicine – a pipe dream or legitimate goal? Read more

day: Virtual Conference Day

Opening Keynote Address: Chromatin-modifying and RNA-modifying Enzyme Inhibitors as Precision Cancer Therapeutics 8:00 am

The history of epigenetics – from first wave to present day  Benefits of RNA modifying enzymes as a target  Precise combination therapeutics in cancer (including epigenetics) for patients in the future Read more

day: Virtual Conference Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.